Dr. Carey on Everolimus in Metastatic Breast Cancer
Lisa A. Carey, MD
Published Online: Friday, April 5, 2013
Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.
Everolimus, an mTOR inhibitor, has demonstrated benefit to women with acquired endocrine resistance. These patients are treated with an aromatase inhibitor, respond briefly, but eventually develop resistance. It has been seen, Carey says, that adding everolimus to any aromatase inhibitor still produces beneficial results with regard to progression-free survival. Everolimus, and targeting the mTOR pathway in general, is a promising arena in metastatic acquired resistance to endocrine therapies.
Future studies will move everolimus into the adjuvant setting and analyze whether it helps to augment the effectiveness of endocrine therapy.
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, provides an outlook on the treatment of HER2-positive breast cancer.
Success rates for lumpectomies or mastectomies are high with respect to survival, with up to 98% long-term survival rates for surgery and/or radiotherapy, but what if similar results could be achieved by substituting targeted medications for therapy?
The US Supreme Court’s landmark decision last June, mandating that an individual’s genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.